A clinical-stage biotechnology company focused on therapies that modulate the innate immune system to treat autoimmune and inflammatory diseases. Its lead programs have targeted conditions such as multiple sclerosis, with value tied largely to clinical trial progress and regulatory milestones. Inves...
1 member of Congress has disclosed 5 trades in Inate Immunotherapeutics Ltd. (INIM), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-10-31 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2019-10-31 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2019-10-04 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2019-10-04 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2019-10-04 | MICHAEL T. MCCAUL | buy | $1K – $15K |